Chart: the 5 ways CSL Limited makes money

Decoding the amazing product lines which drive CSL Limited (ASX:CSL).

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) is a real standout among Australia's listed healthcare companies.

I find the products both mind-boggling and awe inspiring for their ability to save lives. The products may be complex and very specialised, but it's important to understand how they contribute to the company's core revenue streams before investing.

How does CSL Limited make money?

CSL Limited's revenues can be sorted into five product categories:

CSL Revenue

Source: CSL Limied 2015 Annual report. Chart: Author

Immunoglobulins (41%)

These are antibodies used by the immune system to protect us against illness. CSL's products, including Hizentra, are used to treat and prevent infections and to treat autoimmune diseases.

People often need these products if they are born without the immunities and antibodies they need, known as Primary immunodeficiency. According to research in the Journal of Molecular Diagnostics, this impacts 1-in-500 people in the U.S.

Other/specialty products (27%)

This includes products like Kcentra, which helps blood clotting for patients that need urgent surgery but are taking the blood thinner Warfarin, which prevents blood clots.

Another example is Berinert, which treats the rare Hereditary Angioedema condition. This is the lack of a certain blood protein which can cause painful and dangerous swelling.

Albumin (14%)

Albumin is the most common type of protein found in our blood plasma and its role is to stabilise blood pressure. CSL's Albumin products help to restore blood volume and pressure in patients after trauma or surgery. It is also used for treating burns.

Plasma-derived coagulants (10%)

These products help blood clotting and include products to treat Haemophilia A, B and other acute bleeding disorders.

Helixate (8%)

This controls and prevents bleeding in both adults and children with haemophilia A.

Foolish takeaway

The products CSL produces are well regarded and, supported by patents and trademarks, can offer a significant competitive advantage.

On top of that CSL's financial position is fantastic, allowing year after year of growth and high compounding returns for shareholders, making it one of very few companies I would be willing to pay a premium price to own.

Motley Fool contributor Regan Pearson has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »